Are electronic signatures legally valid?

Yes. Electronic signatures are legally equivalent to handwritten signatures under the federal ESIGN Act (15 U.S.C. §7001) and UETA in most states, provided intent, consent, attribution, and record retention requirements are met.

Do I need a BAA for eSignature vendors?

If the protocol or consent process involves protected health information, execute a Business Associate Agreement with the eSignature provider to comply with HIPAA privacy and security rules (45 CFR §§160–164).

When is notarization required?

Notarization is uncommon for study protocols but may be required for site-specific legal documents or POAs; state rules vary, so verify local requirements before routing for notarization.

How do I correct a signed protocol?

Do not alter a signed version. Issue an amendment version, document the change history, obtain required approvals, and distribute the new effective version to sites.

Who may sign the protocol?

Authorized signers typically include the principal investigator and an institutional representative with delegated authority. Confirm signature authority in institutional policies or sponsor delegation logs.

How long must signed protocols be retained?

Retain protocols per applicable rules: HIPAA six years (45 CFR §164.530(j)), IRS three years (IRC §6501(a)), and sponsor or regulatory requirements which may extend retention.

Electronic Signature
Templates
Healthcare
Healthcare Study Protocol

Healthcare Study Protocol

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE STUDY PROTOCOL

Administrative Information

Study Title Protocol Identifier Sponsor / Funding Entity Principal Investigator Primary Site Address

Sponsor Contact: Telephone:

Protocol Synopsis

Study Phase and Design

Phase: Phase 1 Phase 2 Phase 3 Observational

Study Design Summary Primary Objective Secondary Objectives

Background and Rationale

Study Population

Estimated Enrollment Inclusion Criteria Exclusion Criteria

Study Procedures and Schedule

Screening and Enrollment Visit Schedule Assessments and Measurements

Safety, Monitoring and Reporting

Data Safety Monitoring Plan (DSMP)

Data Management and Confidentiality

Source Data and Record Retention

Confidentiality: All personally identifiable information collected under this protocol shall be handled in accordance with institutional policies and applicable law. Access to identifiable data will be limited to authorized study personnel and auditors. De-identified datasets will be used for analysis whenever permissible.

HIPAA Authorization Required

I certify that a HIPAA-compliant authorization will be obtained from each participant when required by law or institutional policy.

Authorization Expiration Date

Ethics and Regulatory Review

This protocol requires review and approval by an independent ethics committee or institutional review board (IRB) prior to enrollment. Any amendments to the protocol that materially affect participant safety or study conduct must be submitted for review and approval before implementation.

IRB / Ethics Committee Reference

Consent and Withdrawal

Informed consent will be obtained in writing from each prospective participant or their legally authorized representative prior to any study-specific procedures. Subjects may withdraw consent at any time without penalty; withdrawal will not affect ongoing clinical care. The process for re-consent following protocol changes is described below.

Re-consent Procedure

Protocol Amendments and Termination

Participant Data Collection Template

This template is to be used for source documentation and CRF design. It is not the consent form; consent must be documented separately.

Participant Full Legal Name Date of Birth Gender Contact Address Telephone Emergency Contact (Name & Relationship)

Insurance and Medical History

Insurance Provider Policy / Group Number Subscriber Name Current Medications Allergies Prior Surgeries / Hospitalizations Chronic Conditions

Administrative Certifications

By signing below, the parties certify that this protocol accurately describes the conduct of the study, that necessary resources are available, and that the study will be conducted in accordance with applicable ethical standards and laws. Any substantive deviation from this protocol requires documented approval by the Sponsor and the Principal Investigator and, where applicable, prior approval by the applicable ethics committee.

Principal Investigator:

By:

Date:

Sponsor / Authorized Representative:

By:

Date:

What a Healthcare Study Protocol Is and why it matters

A Healthcare Study Protocol is a written plan that describes the objectives, design, methodology, statistical considerations, and operational procedures for a clinical or observational study. It defines participant eligibility, informed consent processes, safety monitoring, data collection, and analysis approaches so that study conduct is consistent, reproducible, and auditable across sites and investigators.

Why a clear Protocol improves study integrity

A well-structured protocol reduces regulatory risk, supports informed consent, and ensures consistent data collection across sites. It also provides the basis for IRB review, sponsor oversight, and reproducible results under applicable federal requirements.

Who typically prepares and relies on the protocol

Clear responsibility assignments in the protocol reduce ambiguity and support audit readiness during monitoring and inspection.

Principal Investigators and Sub-Investigators responsible for clinical oversight and participant safety.
Institutional Review Boards and Ethics Committees reviewing human subject protections and consent language.
Sponsors and clinical operations teams who monitor compliance, budgets, and data integrity.

Essential sections to include in a professional protocol

Include standardized sections so reviewers and sites can find key information quickly. Each section should be written clearly, use defined terms, and reference supporting documents such as informed consent forms and safety reporting plans.

Title Page

Protocol identifier, full study title, sponsor, version and effective date, and contact details for the sponsor and principal investigator.

Synopsis

Concise study summary with objectives, design, primary endpoints, sample size, key inclusion/exclusion criteria, and duration of participation.

Study Design

Detailed description of study arms, randomization, blinding, visit schedule, procedures, and timing of assessments.

Safety and Reporting

Adverse event definitions, reporting timelines, safety monitoring plan, DSMB responsibilities, and sponsor contact information.

Statistical Plan

Primary and secondary analyses, sample size calculation, handling of missing data, and statistical significance thresholds.

Regulatory & Ethics

IRB approval procedures, informed consent process, data privacy measures (HIPAA), and record retention policies.

Stepwise process to finalize a Healthcare Study Protocol

Follow a defined sequence from drafting to approval to make the protocol approvable and implementable across study sites.

01

Drafting: Compile objectives, methods, and schedules into a single document.
02

Internal Review: Sponsor and clinical teams review for scientific and operational feasibility.
03

IRB Submission: Submit protocol plus consent and supporting docs to IRB for review.
04

Approval and Distribution: Obtain written IRB approval, distribute final version to sites and archive previous versions.

How to configure a typical digital workflow for protocol approval

Set up the digital route to mirror the approved review path so signatures and approvals are captured in order.

Field	Configuration
Reviewer Order	Sequential routing: PI → Sponsor Medical Monitor → Regulatory Lead
Authentication	Email + SMS code for external signers; SSO for internal users
Attachments	Attach consent forms, CVs, and delegation logs as required
Audit Trail	Enable full audit logging with timestamps and IP addresses

Technical considerations for eSignature and eSubmission

Choose configuration that preserves legal validity, retains audit logs, and meets sponsor and IRB expectations.

Authentication: Support for email, SMS, or multi-factor authentication
Compliance: HIPAA BAA availability and 21 CFR Part 11 support where required
File Formats: Accepts PDF and DOCX with audit trail export

Typical eSubmission and eSignature flow for protocol execution

A consistent digital flow reduces turnaround time and creates an auditable record for compliance and monitoring.

Upload Document: Upload final protocol PDF to the signing platform
Place Fields: Add signature, date, and checkbox fields where required
Route to Signers: Send in defined order or via role-based links
Store Record: Capture signed PDF plus completion certificate

Security and compliance elements to verify

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest

HIPAA BAA: BAA available for protected health information

Audit Trail: Timestamped events, IP, and action log

Access Controls: Role-based permissions and SSO support

Regulatory Certs: SOC 2 Type II and ISO 27001

FDA Compliance: 21 CFR Part 11 capabilities available

Potential penalties and risks from incorrect protocols

HIPAA Violations: Civil fines (45 CFR §160–164)

Invalid Consent: Risk of unusable data and enrollment halts

Regulatory Sanctions: FDA citations and study suspension

Financial Penalties: Sponsor liability for noncompliance

Protocol Deviations: Data integrity and audit failures

Legal Exposure: Litigation and reputational harm

Common mistakes to avoid when preparing a Healthcare Study Protocol

Vague eligibility criteria that increase screen failures and introduce selection bias across sites.
Missing or inconsistent version control leading to sites using different procedure sets during enrollment.
Insufficient safety monitoring language that delays adverse event reporting and regulatory escalation.
Failure to include required privacy language or BAA terms when collecting protected health information.

Key timelines and regulatory reporting expectations

Plan milestones upfront and assign owners to avoid missed filings or late safety reports.

IRB Submission Turnaround:

Typical review takes 2–8 weeks depending on IRB workload

Adverse Event Reporting:

Serious unexpected events: 7 calendar days for life-threatening cases (21 CFR 312.32)

Continuing Review:

Annual or as-specified by IRB; Common Rule updates may change requirements

Site Initiation:

Occurs after IRB approval and PI sign-off; timing varies by site readiness

Final Study Report:

Submit per sponsor contract and registry requirements (timing specified in protocol)

eSignature vendor comparison for Healthcare Study Protocol workflows

Pricing and feature availability differ across vendors; signNow is listed first for direct comparison. Confirm plan details and HIPAA options with each vendor.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Yes	Yes	Yes	Yes
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently asked questions about Healthcare Study Protocols and e-signing

Answers address common legal, technical, and operational questions encountered when finalizing and routing protocols electronically.

Need help? Contact support

Are electronic signatures legally valid?
Yes. Electronic signatures are legally equivalent to handwritten signatures under the federal ESIGN Act (15 U.S.C. §7001) and UETA in most states, provided intent, consent, attribution, and record retention requirements are met.
Do I need a BAA for eSignature vendors?
If the protocol or consent process involves protected health information, execute a Business Associate Agreement with the eSignature provider to comply with HIPAA privacy and security rules (45 CFR §§160–164).
When is notarization required?
Notarization is uncommon for study protocols but may be required for site-specific legal documents or POAs; state rules vary, so verify local requirements before routing for notarization.
How do I correct a signed protocol?
Do not alter a signed version. Issue an amendment version, document the change history, obtain required approvals, and distribute the new effective version to sites.
Who may sign the protocol?
Authorized signers typically include the principal investigator and an institutional representative with delegated authority. Confirm signature authority in institutional policies or sponsor delegation logs.
How long must signed protocols be retained?
Retain protocols per applicable rules: HIPAA six years (45 CFR §164.530(j)), IRS three years (IRC §6501(a)), and sponsor or regulatory requirements which may extend retention.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now